Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.

Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, Darras BT, Muntoni F, Mercuri E, De Vivo DC, Bishop KM, Schneider E, Bennett CF, Foster R, Farwell W; CS2 and CS12 Study Groups.

Muscle Nerve. 2019 Jul 12. doi: 10.1002/mus.26633. [Epub ahead of print]

PMID:
31298747
2.

Neurofilament as a potential biomarker for spinal muscular atrophy.

Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G, Staropoli J, McCampbell A, Petrillo M, Stebbins C, Fradette S, Farwell W, Sumner CJ.

Ann Clin Transl Neurol. 2019 Apr 17;6(5):932-944. doi: 10.1002/acn3.779. eCollection 2019 May.

3.

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC; ISIS-396443-CS2/ISIS-396443-CS12 Study Groups.

Neurology. 2019 May 21;92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527. Epub 2019 Apr 24.

4.

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients.

Lochmüller H, Evans D, Farwell W, Finkel R, Goemans N, de Lemus M, Matyushenko V, Muntoni F, Ouillade MC, Schwersenz I, Wilson P.

J Neuromuscul Dis. 2018;5(2):131-133. doi: 10.3233/JND-180325. No abstract available.

5.

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group.

N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.

6.

Therapy for Spinal Muscular Atrophy.

Finkel RS, Farwell W.

N Engl J Med. 2018 Feb 1;378(5):487-488. doi: 10.1056/NEJMc1715769. No abstract available.

PMID:
29385371
7.

Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.

Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD.

Orphanet J Rare Dis. 2017 Nov 28;12(1):175. doi: 10.1186/s13023-017-0724-z.

8.

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group.

N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.

9.

The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.

Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME.

Blood Cells Mol Dis. 2017 Mar;63:62-65. doi: 10.1016/j.bcmd.2017.01.008. Epub 2017 Jan 16.

PMID:
28178599
10.

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function.

He P, Kerr D, Marbury T, Ries D, Farwell W, Stecher S, Dong Y, Wei D, Rogge M.

J Clin Pharmacol. 2014 Dec;54(12):1383-90. doi: 10.1002/jcph.353. Epub 2014 Jul 3.

11.

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators.

Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].

PMID:
24067398
12.

Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey.

Paik JM, Farwell WR, Taylor EN.

Osteoporos Int. 2012 Jun;23(6):1727-36. doi: 10.1007/s00198-011-1776-x. Epub 2011 Sep 20.

13.

The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study.

Farwell WR, Lourenco C, Holmberg E, Hall RB, D'Avolio L, Lawler EV, Michael Gaziano J.

Cancer Causes Control. 2011 Oct;22(10):1453-9. doi: 10.1007/s10552-011-9820-x. Epub 2011 Jul 20.

14.

Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation.

Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, Choong K, Lakshman K, Mazer NA, Coviello AD, Knapp PE, Ulloor J, Zhang A, Brooks B, Nguyen AH, Eder R, LeBrasseur N, Elmi A, Appleman E, Hede-Brierley L, Bhasin G, Bhatia A, Lazzari A, Davis S, Ni P, Collins L, Bhasin S.

J Gerontol A Biol Sci Med Sci. 2011 Oct;66(10):1090-9. doi: 10.1093/gerona/glr100. Epub 2011 Jun 22.

15.

Statins and prostate cancer diagnosis and grade in a veterans population.

Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM.

J Natl Cancer Inst. 2011 Jun 8;103(11):885-92. doi: 10.1093/jnci/djr108. Epub 2011 Apr 15.

16.

Comparative effectiveness research and medical informatics.

D'Avolio LW, Farwell WR, Fiore LD.

Am J Med. 2010 Dec;123(12 Suppl 1):e32-7. doi: 10.1016/j.amjmed.2010.10.006.

PMID:
21184865
17.

Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey.

Gutiérrez OM, Farwell WR, Kermah D, Taylor EN.

Osteoporos Int. 2011 Jun;22(6):1745-53. doi: 10.1007/s00198-010-1383-2. Epub 2010 Sep 17.

18.

Prevalence and characteristics of tinnitus among US adults.

Shargorodsky J, Curhan GC, Farwell WR.

Am J Med. 2010 Aug;123(8):711-8. doi: 10.1016/j.amjmed.2010.02.015.

PMID:
20670725
19.

Evaluation of a generalizable approach to clinical information retrieval using the automated retrieval console (ARC).

D'Avolio LW, Nguyen TM, Farwell WR, Chen Y, Fitzmeyer F, Harris OM, Fiore LD.

J Am Med Inform Assoc. 2010 Jul-Aug;17(4):375-82. doi: 10.1136/jamia.2009.001412.

20.

Adverse events associated with testosterone administration.

Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S.

N Engl J Med. 2010 Jul 8;363(2):109-22. doi: 10.1056/NEJMoa1000485. Epub 2010 Jun 30.

21.

Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey.

Farwell WR, Taylor EN.

CMAJ. 2010 Feb 9;182(2):137-41. doi: 10.1503/cmaj.090329. Epub 2009 Dec 14.

22.

Primary care visit duration and quality: does good care take longer?

Chen LM, Farwell WR, Jha AK.

Arch Intern Med. 2009 Nov 9;169(20):1866-72. doi: 10.1001/archinternmed.2009.341.

PMID:
19901138
23.

Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.

Hernandez RK, Farwell W, Cantor MD, Lawler EV.

J Am Geriatr Soc. 2009 Nov;57(11):1997-2003. doi: 10.1111/j.1532-5415.2009.02488.x. Epub 2009 Sep 28.

PMID:
19793162
24.

Lack of cholesterol awareness among physicians who smoke.

Scranton RE, Farwell WR, Gaziano JM.

Int J Environ Res Public Health. 2009 Feb;6(2):635-42. doi: 10.3390/ijerph6020635. Epub 2009 Feb 11.

25.

Serum bicarbonate, anion gap and insulin resistance in the National Health and Nutrition Examination Survey.

Farwell WR, Taylor EN.

Diabet Med. 2008 Jul;25(7):798-804. doi: 10.1111/j.1464-5491.2008.02471.x.

PMID:
18644066
26.

The relationship between total plasma carotenoids and risk factors for chronic disease among middle-aged and older men.

Farwell WR, Michael Gaziano J, Norkus EP, Sesso HD.

Br J Nutr. 2008 Oct;100(4):883-9. doi: 10.1017/S0007114508944111. Epub 2008 Mar 12.

PMID:
18334043
27.

The association between statins and cancer incidence in a veterans population.

Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM.

J Natl Cancer Inst. 2008 Jan 16;100(2):134-9. doi: 10.1093/jnci/djm286. Epub 2008 Jan 8.

PMID:
18182618
28.

Trends in prostate-specific antigen testing from 1995 through 2004.

Farwell WR, Linder JA, Jha AK.

Arch Intern Med. 2007 Dec 10;167(22):2497-502.

PMID:
18071173
29.

Serum anion gap and blood pressure in the national health and nutrition examination survey.

Taylor EN, Forman JP, Farwell WR.

Hypertension. 2007 Aug;50(2):320-4. Epub 2007 Jun 11.

PMID:
17562979
30.

Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction.

Farwell WR, Sesso HD, Buring JE, Gaziano JM.

Am J Cardiol. 2005 Oct 15;96(8):1129-34. Epub 2005 Aug 29.

PMID:
16214451
31.

Weight gain and new onset diabetes associated with olanzapine and risperidone.

Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM.

J Gen Intern Med. 2004 Dec;19(12):1200-5.

32.

Effects of ischemic tolerance on mRNA levels of IP3R1, beta-actin, and neuron-specific enolase in hippocampal CA1 area of the gerbil brain.

Farwell W, Simonyi A, Scott H, Zhang JP, Carruthers V, Madsen R, Johnson J, Sun GY.

Neurochem Res. 1998 Apr;23(4):539-42.

PMID:
9566589

Supplemental Content

Loading ...
Support Center